

Company Number: 603086

Almeg Podiatry Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Almeg Podiatry Limited
CONTENTS

| | Page |
|-----------------------------------|-------------|
| Directors and Other Information | 3 |
| Statement of Financial Position | 4 |
| Notes to the Financial Statements | 5 - 8 |

Almeg Podiatry Limited
DIRECTORS AND OTHER INFORMATION

| | |
|---|--|
| Directors | Megan Staunton Alistair France |
| Company Secretary | Megan Staunton |
| Company Number | 603086 |
| Registered Office and Business Address | c/o Megan Staunton Main Street Castlebar Mayo Ireland |
| Accountants | Michael Kelly & Co Certified Public Accountants Spencer Street Castlebar Mayo Ireland |
| Bankers | Bank of Ireland, Ellison Street, Castlebar, County Mayo |

Almeg Podiatry Limited

STATEMENT OF FINANCIAL POSITION

as at 30 April 2025

| | Notes | 2025 € | 2024 € |
|---|-------|-----------------------|-----------------------|
| Fixed Assets | | | |
| Tangible assets | 5 | <u>35,414</u> | <u>39,424</u> |
| Current Assets | | | |
| Stocks | 6 | 12,993 | 12,797 |
| Debtors | 7 | 375 | 50,450 |
| Cash at bank and in hand | | <u>250,361</u> | <u>146,966</u> |
| | | <u>263,729</u> | <u>210,213</u> |
| Creditors: amounts falling due within one year | 8 | <u>(32,235)</u> | <u>(36,555)</u> |
| Net Current Assets | | <u>231,494</u> | <u>173,658</u> |
| Total Assets less Current Liabilities | | <u><u>266,908</u></u> | <u><u>213,082</u></u> |
| Capital and Reserves | | | |
| Called up share capital presented as equity | | 100 | 100 |
| Retained earnings | 9 | <u>266,808</u> | <u>212,982</u> |
| Shareholders' Funds | | <u><u>266,908</u></u> | <u><u>213,082</u></u> |

We as Directors of Almeg Podiatry Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the board on 20 January 2026 and signed on its behalf by:

Megan Staunton
Director

Alistair France
Director

Almeg Podiatry Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Almeg Podiatry Limited is a company limited by shares incorporated in Ireland. The registered office of the company is c/o Megan Staunton, Main Street, Castlebar, Mayo, Ireland which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared in accordance with FRS 105 "The Financial Reporting Standard for Micro-Entities applicable in the UK and Republic of Ireland" (FRS 105).

Basis of preparation

The financial statements have been prepared in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Accounting Convention

The financial statements are prepared under the historical cost convention.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Functional Currency

The functional currency of the financial statements is the euro.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

| | | |
|----------------------------------|---|---------------------|
| Fixtures, fittings and equipment | - | 12.5% Straight line |
| Motor vehicles | - | 20% Straight line |

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Almeg Podiatry Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

Employed benefits

The company provides a range of benefits, including annual bonus arrangements, paid holiday arrangements and defined contribution pension schemes.

Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the period in which the service is rendered.

Retirement Benefits

Retirement benefits are met by payments to a defined contribution pension fund. Contributions are charged to the profit and loss in the year in which they fall due.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Transactions, during the year, which are denominated in foreign currencies are translated at the rates of exchange ruling at the date of the transaction. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

| | | |
|---|--------------------------|--------------------------|
| 3. Operating profit | 2025 | 2024 |
| | € | € |
| Operating profit is stated after charging/(crediting): | | |
| Depreciation of tangible assets | 14,705 | 21,174 |
| (Profit) on disposal of tangible assets | (110) | - |
| Government grants received | (1,412) | - |
| | <u><u> </u></u> | <u><u> </u></u> |

4. Employees

The average monthly number of employees, including directors, during the financial year was 5, (2024 - 5).

| | | |
|--------------------------|--------------------------|--------------------------|
| | 2025 | 2024 |
| | Number | Number |
| Administration Part time | 2 | 2 |
| Qualified Podiatrist | 3 | 3 |
| | <u><u> </u></u> | <u><u> </u></u> |
| | 5 | 5 |

Almeg Podiatry Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

5. Tangible assets

| | Fixtures, fittings and equipment € | Motor vehicles € | Total € |
|-------------------------------|---|------------------------|----------------------|
| Cost | | | |
| At 1 May 2024 | 98,035 | 44,600 | 142,635 |
| Additions | 19,615 | - | 19,615 |
| Disposals | - | (44,600) | (44,600) |
| | <u>117,650</u> | <u>-</u> | <u>117,650</u> |
| Depreciation | | | |
| At 1 May 2024 | 67,531 | 35,680 | 103,211 |
| Charge for the financial year | 14,705 | - | 14,705 |
| On disposals | - | (35,680) | (35,680) |
| | <u>82,236</u> | <u>-</u> | <u>82,236</u> |
| Net book value | | | |
| At 30 April 2025 | <u>35,414</u> | <u>-</u> | <u>35,414</u> |
| At 30 April 2024 | <u>30,504</u> | <u>8,920</u> | <u>39,424</u> |

6. Stocks

| | 2025 € | 2024 € |
|-------------------------------------|----------------------|---------------|
| Finished goods and goods for resale | <u>12,993</u> | <u>12,797</u> |

The replacement cost of stock did not differ significantly from the figures shown.

7. Debtors

| | 2025 € | 2024 € |
|---------------|-------------------|---------------|
| Trade debtors | 375 | 450 |
| Other debtors | - | 50,000 |
| | <u>375</u> | <u>50,450</u> |

**8. Creditors
Amounts falling due within one year**

| | 2025 € | 2024 € |
|-----------------------------|----------------------|---------------|
| Taxation | 17,405 | 17,822 |
| Directors' current accounts | 263 | 795 |
| Accruals | 14,567 | 17,938 |
| | <u>32,235</u> | <u>36,555</u> |

9. Income Statement

| | 2025 € | 2024 € |
|-------------------------------|-----------------------|----------------|
| At 1 May 2024 | 212,982 | 150,767 |
| Profit for the financial year | <u>53,826</u> | <u>62,215</u> |
| At 30 April 2025 | <u>266,808</u> | <u>212,982</u> |

Almeg Podiatry Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

10. Capital commitments

The company had no material capital commitments at the financial year-ended 30 April 2025.

11. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

12. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 20 January 2026.